Nature Communications (Nov 2018)
Targeting 17q23 amplicon to overcome the resistance to anti-HER2 therapy in HER2+ breast cancer
- Yunhua Liu,
- Jiangsheng Xu,
- Hyun Ho Choi,
- Cecil Han,
- Yuanzhang Fang,
- Yujing Li,
- Kevin Van der Jeught,
- Hanchen Xu,
- Lu Zhang,
- Michael Frieden,
- Lifei Wang,
- Haniyeh Eyvani,
- Yifan Sun,
- Gang Zhao,
- Yuntian Zhang,
- Sheng Liu,
- Jun Wan,
- Cheng Huang,
- Guang Ji,
- Xiongbin Lu,
- Xiaoming He,
- Xinna Zhang
Affiliations
- Yunhua Liu
- Department of Medical and Molecular Genetics, Indiana University School of Medicine
- Jiangsheng Xu
- Department of Biomedical Engineering and Comprehensive Cancer Center, The Ohio State University
- Hyun Ho Choi
- Department of Cancer Biology, The University of Texas MD Anderson Cancer Center
- Cecil Han
- Department of Cancer Biology, The University of Texas MD Anderson Cancer Center
- Yuanzhang Fang
- Department of Medical and Molecular Genetics, Indiana University School of Medicine
- Yujing Li
- Department of Medical and Molecular Genetics, Indiana University School of Medicine
- Kevin Van der Jeught
- Department of Medical and Molecular Genetics, Indiana University School of Medicine
- Hanchen Xu
- Department of Medical and Molecular Genetics, Indiana University School of Medicine
- Lu Zhang
- Department of Medical and Molecular Genetics, Indiana University School of Medicine
- Michael Frieden
- Department of Medical and Molecular Genetics, Indiana University School of Medicine
- Lifei Wang
- Department of Medical and Molecular Genetics, Indiana University School of Medicine
- Haniyeh Eyvani
- Department of Medical and Molecular Genetics, Indiana University School of Medicine
- Yifan Sun
- Department of Medical and Molecular Genetics, Indiana University School of Medicine
- Gang Zhao
- Department of Electronic Science and Technology, School of Information Science and Technology, University of Science and Technology of China
- Yuntian Zhang
- Department of Biomedical Engineering and Comprehensive Cancer Center, The Ohio State University
- Sheng Liu
- Department of Medical and Molecular Genetics, Indiana University School of Medicine
- Jun Wan
- Department of Medical and Molecular Genetics, Indiana University School of Medicine
- Cheng Huang
- Drug Discovery Laboratory, School of Pharmacy, Shanghai University of Traditional Chinese Medicine
- Guang Ji
- Institute of Digestive Diseases, Longhua Hospital, Shanghai University of Traditional Chinese Medicine
- Xiongbin Lu
- Department of Medical and Molecular Genetics, Indiana University School of Medicine
- Xiaoming He
- Department of Biomedical Engineering and Comprehensive Cancer Center, The Ohio State University
- Xinna Zhang
- Department of Medical and Molecular Genetics, Indiana University School of Medicine
- DOI
- https://doi.org/10.1038/s41467-018-07264-0
- Journal volume & issue
-
Vol. 9,
no. 1
pp. 1 – 16
Abstract
The 17q23 amplicon containing the WIP1 oncogene is frequently amplified in HER2+ breast cancer. Here they find MIR21 to be present in WIP1-containing amplicons, and report nanoparticle based co-delivery of WIP1 and miR-21 inhibitors to be effective in trastuzumab-resistant HER2+ breast cancer.
